Comparative Pharmacology
Head-to-head clinical analysis: DUREZOL versus PRED MILD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUREZOL versus PRED MILD.
DUREZOL vs PRED MILD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing immune cell migration and cytokine release.
Prednisolone acetate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2 and reduction of inflammatory mediators such as prostaglandins and leukotrienes.
1 drop of 0.1% ophthalmic solution in the affected eye(s) four times daily for up to 14 days.
1 to 2 drops in the affected eye(s) every hour during the day and every 2 hours at night until a favorable response is obtained, then reduce to 1 drop every 4 hours, and later to 1 drop 3 to 4 times daily as needed to control symptoms.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours in adults; prolonged to 24–36 hours in hepatic impairment.
The terminal elimination half-life of prednisolone is approximately 2.1-3.5 hours. Clinically, this short half-life supports once-daily dosing for many conditions, with minimal accumulation upon repeated administration.
Renal excretion of unchanged drug accounts for 30% of clearance; biliary/fecal elimination accounts for 60%, with the remainder as metabolites.
Prednisolone is primarily excreted renally, with approximately 70-80% of the dose eliminated as metabolites in urine (including glucuronides and sulfates) and less than 10% as unchanged drug. Biliary/fecal excretion accounts for about 20% of the dose.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid